874766-68-4

Upstream product

• 75-09-2 dichloromethane 
• 2312-23-4 m-chlorophenylhydrazine hydrochloride 
• 372-31-6 ethyl 4,4,4-trifluoroacetoacetate 

Downstream Products

• 1384431-63-3 4-diazo-1-(3-chlorophenyl)-3-trifluoromethylpyrazolin-5-one 
• 1384431-79-1 diethyl 1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-furo[2,3-c]pyrazole-4,5-dicarboxylate 
• 1010454-10-0 4-[1-(3-chlorophenyl)-3-(trifluoromethyl)pyrazol-5-yloxy]-1-[5-(trifluoromethyl)-2-pyridyl]-piperidine 

Relevant academic research and scientific papers

Novel hybrids of 3-n-butylphthalide and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents

Abstract Fourteen hybrids (10a-g, 11a-g) of 3-n-butylphthalide (NBP) and edaravone (Eda) analogues have been designed and synthesized as potential anti-ischemic stroke agents. In vitro biological studies showed that compounds 10d and 10g exhibited more potent anti-platelet aggregation than ticlopidine (Ticlid), aspirin (ASP) and NBP. Compound 10g more significantly prevented H2O2-mediated neuronal cell (PC12) death than NBP, Eda or NBP together with Eda. Meanwhile, 10g also possessed potent radical scavenging effects on hydroxyl radical (·OH) and superoxide anion radical (·O2-). Our findings may provide new insights into the development of these hybrids, like 10g, for the intervention of ischemic stroke.

2-(pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3 (2H)-One 1, 1-dioxides and compositions and method of use thereof

2-(Pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3(2H)-one 1,1-dioxides, pharmaceutical compositions containing them and methods for the treatment of degenerative diseases utilizing them.